ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 22

Adenosine a2A Receptor (A2AR) Stimulation Inhibits Osteoclast Differentiation and Promotes Osteoblast Formation By Regulation of Axon Guidance Proteins

Aranzazu Mediero1, Miguel Perez-Aso2 and Bruce N. Cronstein3, 1Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 2545 1st Ave., New York University, New York City, NY, 3NYU School of Medicine, Division of Rheumatology, New York, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Adenosine receptors, Communication, osteoblasts and osteoclasts

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts and Bone Remodeling

Session Type: Abstract Submissions (ACR)

Background/Purpose Semaphorins (Sema), axonal guidance proteins, play a role in communication between osteoclast and osteoblast. Thus, sema4D, secreted by osteoclasts, binds to its receptor PlexinB1 on osteoblasts to inhibit osteoblast differentiation and function whereas sema3A, produced by osteoblasts, binds to PlexinA1/Neuropilin-1 to both inhibit RANKL-induced osteoclast differentiation and stimulate osteoblast differentiation and function. Because stimulation of A2AR diminishes osteolysis we asked whether A2AR activation regulates bone homeostasis by regulating osteoclast and osteoblast expression of semaphorins.

Methods Osteoclast and osteoblast differentiation were studied in primary murine bone marrow culture as the number of TRAP-positive or Alizarin Red-positive cells, respectively, after challenge in the presence/absence of CGS21680 (A2A agonist) 1µM and ZM241385 (A2AR antagonist) 1µM together with recombinant Sema4D or Sema3A 10ng/ml each. Sema3A/PlexinA1/Neuropilin-1 and Sema4D/PlexinB1 expression were studied by RT-PCR and Western Blot in bone marrow-derived osteoclasts and osteoblasts in the presence/absence of CGS21680 and ZM241385 1µM each. RANKL and Osteoprotegerin (OPG) levels were studied by RT-PCR. β-catenin activation was studied in primary osteoblast culture. Cytoskeleton changes were studied in osteoclasts.

Results RANKL induced a 2.5±0.1 fold increase in Sema4D mRNA (p<0.001,n=4) in osteoclasts which was blocked by CGS21680 (1.3±0.3 fold change, p<0.001,n=4). In contrast, PlexinA1 mRNA was enhanced by CGS21680 (9.3±0.7 fold increase vs 4.9±0.6 for RANKL, p<0.001,n=4) but Neuropilin-1 mRNA was unchanged. Sema3A mRNA increased 3.5±0.5 fold during osteoblast differentiation and CGS21680 enhanced this increase (8.7±0.2 fold, p<0.001,n=4); PlexinB1 mRNA was increased 2 fold during osteoblast differentiation and was not altered by CGS21680. Similar changes were observed at the protein level. CGS21680 decreased RANKL expression and increased OPG expression in osteoblasts. Total and nuclear β-catenin expression were increased in osteoblasts after CGS21680 treatment and this increase was abrogated by ZM241385. Sema4D increased RhoA phosphorylation and FAK activation in osteoclast precursors and these effectswere reversed in the presence of CGS21680.

Conclusion A2AR activation diminishes secretion of Sema4D by osteoclasts and enhances secretion of Sema3A by osteoblasts leading to an increase in osteoblast differentiation and function, and, in combination with the suppressive effects of A2AR on osteoclast differentiation and function, diminishes bone osteolysis.


Disclosure:

A. Mediero,
None;

M. Perez-Aso,
None;

B. N. Cronstein,

Canfite Pharma,

1,

AstraZeneca,

2,

Cellgene,

2,

Gilead,

2,

NIH,

2,

NYU School of Medicine,

3,

Bristol-Myers Squibb,

5,

Pfizer Inc,

5,

Eli Lilly and Company,

5,

Rheumatology Reseach Foundation,

6,

ACR,

6,

Arthritis Foundation,

6.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-a2a-receptor-a2ar-stimulation-inhibits-osteoclast-differentiation-and-promotes-osteoblast-formation-by-regulation-of-axon-guidance-proteins/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology